Ventracor chalks up first revenues
By Ruth Beran
Tuesday, 20 September, 2005
Tuesday, 20 September, 2005
Ventracor (ASX:VCR) has received its first revenues, in the form of a cheque from the University of Maryland Medical Centre as payment for a VentrAssist left ventricular assist device (LVAD) recently implanted in a patient as part of its US clinical trial.
The company previously indicated it would reach the milestone before the end of 2005.
Related News
No clear link between paracetamol in pregnancy and autism/ADHD
Existing evidence does not clearly link paracetamol (acetaminophen) use during pregnancy with...
Light at night can increase heart disease risk
Being exposed to bright light at night can significantly increase your chances of developing...
Scientists find new driver of ovarian cancer spread
A cell surface receptor known as F2R could serve as both a diagnostic marker for ovarian cancer...
